E Haydn Walters1,2, Andrew J Palmer3,4,5, Ingrid A Cox1,2, Barbara de Graaff1,2, Hasnat Ahmed1, Julie Campbell1, Petr Otahal1, Tamera J Corte2,6,7, Ian Glaspole2,8,9, Yuben Moodley10,11,12, Nicole Goh2,8, Sacha Macansh13. 1. Menzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia. 2. NHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia. 3. Menzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia. andrew.palmer@utas.edu.au. 4. NHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia. andrew.palmer@utas.edu.au. 5. Centre for Health Policy, School of Population and Global Health, The University of Melbourne, Melbourne, Australia. andrew.palmer@utas.edu.au. 6. Central Clinical School, The University of Sydney, Camperdown, Australia. 7. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia. 8. Alfred Hospital, Melbourne, Australia. 9. Monash University, Melbourne, Australia. 10. Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia. 11. Institute of Respiratory Health, The University of Western Australia, Perth, Australia. 12. Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Australia. 13. Australian Idiopathic Pulmonary Fibrosis Registry, Lung Foundation of Australia, Camperdown, Australia.
Abstract
PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs. METHODS: Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension-five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query RESULTS: A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from - 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61-0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities. CONCLUSIONS: Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.
PURPOSE:Idiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs. METHODS:Participants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension-five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query RESULTS: A total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from - 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61-0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities. CONCLUSIONS: Our study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.
Entities:
Keywords:
EQ-5D-5L; EuroQol five dimension; Health related quality of life; Health state utility values; Idiopathic pulmonary fibrosis
Authors: Ben van Hout; M F Janssen; You-Shan Feng; Thomas Kohlmann; Jan Busschbach; Dominik Golicki; Andrew Lloyd; Luciana Scalone; Paul Kind; A Simon Pickard Journal: Value Health Date: 2012-05-24 Impact factor: 5.725
Authors: Yuben Moodley; Nicole Goh; Ian Glaspole; Sacha Macansh; E Haydn Walters; Sally Chapman; Peter Hopkins; Paul N Reynolds; Christopher Zappala; Wendy Cooper; Annabelle Mahar; Samantha Ellis; Samuel McCormack; William Darbishire; Richard Wood-Baker; Tamera J Corte Journal: Respirology Date: 2014-08-14 Impact factor: 6.424
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Jung Seop Eom; Jeong Ha Mok; Insu Kim; Min Ki Lee; Geewon Lee; Hyemi Park; Ji Won Lee; Yeon Joo Jeong; Won-Young Kim; Eun Jung Jo; Mi Hyun Kim; Kwangha Lee; Ki Uk Kim; Hye-Kyung Park Journal: BMC Pulm Med Date: 2018-08-13 Impact factor: 3.317
Authors: Matthew Kennedy-Martin; Bernhard Slaap; Michael Herdman; Mandy van Reenen; Tessa Kennedy-Martin; Wolfgang Greiner; Jan Busschbach; Kristina S Boye Journal: Eur J Health Econ Date: 2020-06-08
Authors: Ingrid A Cox; Julie Campbell; Barbara de Graaff; Petr Otahal; Tamera J Corte; Yuben Moodley; Peter Hopkins; Sacha Macansh; E Haydn Walters; Andrew J Palmer Journal: Qual Life Res Date: 2022-08-04 Impact factor: 3.440